Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HPV
Biotech
GSK drops ph. 2 HPV vaccine over lack of best-in-class potential
GSK has scrapped a phase 2 human papillomavirus vaccine from its pipeline after deciding the asset won’t have best-in-class potential.
James Waldron
Jul 31, 2024 8:06am
FDA approves self-collection screening for HPV, cervical cancer
May 15, 2024 11:03am
Barinthus HPV drug doesn't prove efficacy
Apr 19, 2024 9:50am
Antiva bags $53M series E to finance future HPV trials
Apr 27, 2023 7:27am
Merck KGaA hands over IL-12 cancer med for up to $121M
Jan 3, 2023 2:17pm
J&J culls Bavarian Nordic pacts for HPV, hep B vax
May 9, 2022 9:47am
